More than 130 suppliers
ISO certified
In-house tech support
we Connect you
Bio-Connect
ProductsBack/Linagliptin [668270-12-0]
Chemical Structure
Chemical Structure
Chemical Structure

Linagliptin [668270-12-0]

Research Use Only
AG-CR1-3618
AdipoGen Life Sciences
CAS Number668270-12-0
DownloadDatasheet
DownloadMSDS
Product group Chemicals
Estimated Purity>98%
Molecular Weight472.5
Price on request
Packing Size
Large volume orders?
Order with a bulk request
More than 130 suppliers
ISO certified
In-house tech support

Overview

  • Supplier
    AdipoGen Life Sciences
  • Product Name
    Linagliptin [668270-12-0]
  • Delivery Days Customer
    10
  • CAS Number
    668270-12-0
  • Certification
    Research Use Only
  • Estimated Purity
    >98%
  • Hazard Information
    Warning
  • Molecular Formula
    C25H28N8O2
  • Molecular Weight
    472.5
  • Scientific Description
    Antidiabetic agent. Highly potent and selective competitive inhibitor of dipeptidyl-peptidase 4 (DPP4; DPP IV; CD26), an enzyme that degrades, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Prevents the inactivation of endogenous GLP-1 and GIP. Shown to restore beta cell function and survival in human isolated islets through GLP-1 stabilization. Improves insulin sensitivity. Anti-inflammatory compound. DPP4 is a cell surface aminopeptidase that exerts diverse biological activities, such as protease activity, association with adenosine deaminase, interaction with the extracellular matrix, regulation of intracellular signal transduction coupled with the control of cell migration and proliferation, and in addition cell surface co-receptor activity mediating viral entry. DPP4 is a viral receptor of human coronaviruses and therefore is investigated as a potential target for SARS-CoV-2 infections. - Chemical. CAS: 668270-12-0. Formula: C25H28N8O2. MW: 472.5. Antidiabetic agent. Highly potent and selective competitive inhibitor of dipeptidyl-peptidase 4 (DPP4; DPP IV; CD26), an enzyme that degrades, glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). Prevents the inactivation of endogenous GLP-1 and GIP. Shown to restore beta cell function and survival in human isolated islets through GLP-1 stabilization. Improves insulin sensitivity. Anti-inflammatory compound.
  • SMILES
    CC#CCN1C(=NC2=C1C(=O)N(CC1=NC3=CC=CC=C3C(C)=N1)C(=O)N2C)N1CCC[C@@H](N)C1
  • Storage Instruction
    2°C to 8°C,-20°C
  • UNSPSC
    12352200

References

  • 8-(3-(R)-aminopiperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydropurine-2,6-dione (BI 1356), a highly potent, selective, long-acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes: M. Eckhardt, et al.; J. Med. Chem. 50, 6450 (2007)
  • Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of BI 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers: S. Hüttner, et al.; J. Clin. Pharmacol. 48, 1171 (2008)
  • (R)-8-(3-amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors: L. Thomas, et al.; J. Pharmacol. Exp. Ther. 325, 175 (2008)
  • Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients: T. Heise, et al.; Diabetes Obes. Metab. 11, 786 (2009)
  • The DPP4 inhibitor linagliptin delays the onset of diabetes and preserves beta-cell mass in non-obese diabetic mice: J. Jelsing, et al.; J. Endocrinol. 214, 381 (2012)
  • The dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob mice: C. Schurmann, et al.; J. Pharmacol. Exp. Ther. 342, 71 (2012)
  • Linagliptin improves insulin sensitivity and hepatic steatosis in diet-induced obesity: M. Kern, et al.; PLoS One 7, e38744 (2012)
  • Emerging DPP-4 inhibitors: focus on linagliptin for type 2 diabetes: B. Gallwitz; Diabetes Metab. Syndr. Obes. 6, 1 (2013) (Review)
  • The DPP-4 inhibitor linagliptin restores beta-cell function and survival in human isolated islets through GLP-1 stabilization: P. Shah, et al.; J. Clin. Endocrinol. Metab. 98, E1163 (2013)
  • Linagliptin: from bench to bedside: J. Doupis; Drug. Des. Devel. Ther. 8, 431 (2014) (Review)